Belimumab in systemic lupus erythematosus
Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, au...
Main Author: | Ankita Srivastava |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Indian Journal of Dermatology |
Subjects: | |
Online Access: | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2016;volume=61;issue=5;spage=550;epage=553;aulast=Srivastava |
Similar Items
-
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
by: Francesca Regola, et al.
Published: (2019-04-01) -
Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study
by: Bruno Miguel Fernandes, et al.
Published: (2020-07-01) -
Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain
by: Silvia Díaz-Cerezo, et al.
Published: (2015-02-01) -
Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report
by: Marco Scarati, et al.
Published: (2017-04-01) -
Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01)